Unknown PHASE4 INTERVENTIONAL 2-arm NCT02094703

The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Urinary Tract Infection in Females

The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Symptomatic Non-complicated Urinary Tract Infection in Females

Sponsor: Astellas Pharma Indonesia Inc.

Conditions Urinary Tract Infection

Interventions Levofloxacin Placebo (for Solifenacin succinate) Solifenacin succinate

Updated 5 times since 2017 Last updated: Mar 19, 2014 Started: Apr 30, 2013 Primary completion: Nov 30, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Urinary Tract Infection, this trial is ongoing. The trial is conducted by Astellas Pharma Indonesia Inc. and has accumulated 5 data snapshots since 2013. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Indonesia Inc.
Dr Cipto Mangunkusumo General Hospital
Pharos Life Corporation

Data source: Dr Cipto Mangunkusumo General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jakarta, Indonesia